The anti-inflammatory drug celecoxib (an inhibitor of the cyclooxygenase 2 and HMGB1/TLR-4 pathways) has been documented to significantly reduce the remote consequences of status epilepticus in rats. Here, PTGS2 is linked to status epilepticus.